U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842810) titled 'Fibroblast Growth Factor 21 in Systemic Lupus Erythematosus' on Feb. 19.
Brief Summary: Systemic lupus erythematosus (SLE) is a chronic disorder characterized by profound immune and metabolic disturbances. It emerges due to a complex interplay of genetic and environmental factors. Alteration in immune cell metabolism is another feature of SLE. Mitochondria, serving as the main regulator of cell metabolism, exhibits pronounced dysfunction in SLE patients.
Kidneys are among the most frequently affected organs in SLE, with 30-40% of patients developing lupus nephritis (LN) over the course of their disease. LN patients exhibit varying ...